Lilly Leaps Into China Broad Diabetes Market, Echoing Sanofi, Novo
This article was originally published in PharmAsia News
Signaling a new direction, Lilly is embracing China's vast county hospital market for its diabetes care products through a new access initiative, following in the footsteps of rivals Sanofi and Novo Nordisk but with a bolder and broader approach.
You may also be interested in...
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.